To understand whether gilteritinib and Pim inhibitor cotreatment enhances c-Myc and Mcl-1 proteasomal degradation through GSK-3β activation, p-GSK-3β (inactivated) and GSK-3β expression was measured in Ba/F3-ITD cells and FLT3-ITD AML patient blasts treated with gilteritinib and/or AZD1208, or DMSO control. The gene discussed is MCL1; the disease is acute myeloid leukemia.